Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chick Eggs Cannot Yield Enough Vaccine For Pandemic: NYAS Swine Flu Mtg.

Executive Summary

If preparation for a possible pandemic is ever going to be sufficient, drug makers need to push for FDA approval of adjuvants and novel technologies in which influenza vaccines can be created, according to a panel of experts

You may also be interested in...



Eggs May Be Culprit In Poor Flu Vaccine Performance This Year

US health authorities, manufacturers investigating why egg-based product appears to have lower effect in adults compared to cell-based flu vaccine.

Novartis’ Cell-based Vaccine: Seasonal Approval With Pandemic Implications

The Flucelvax flu vaccine is the first approved in the U.S. that is derived from cell-based technology instead of the traditional egg-based process. It will be made at Novartis’ Holly Springs, N.C. plant.

Novavax, VaxInnate Receive BARDA Funds For Recombinant Flu Vaccine Development

New processes would speed vaccine production and could improve on efficacy.

Related Content

Topics

UsernamePublicRestriction

Register

PS051133

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel